ArticleJournal of oral & facial pain and headache2026
Efficacy of prolotherapy in temporomandibular joint disorders with hypertonic dextrose and Polydeoxyribonucleotide (PDRN).
Article in Journal of oral & facial pain and headache, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Immuno-Mechanical Signaling Network Integration in Temporomandibular Joint Pathology: A TMID Conceptual Framework.International journal of molecular sciences · 2026Review
- Polydeoxyribonucleotide (PDRN) in Dentistry: Narrative Review for Mechanisms and Emerging Clinical Applications.Tissue engineering and regenerative medicine · 2026Review
- Prolotherapy for temporomandibular joint disorders: an updated comprehensive review.Journal of the Korean Association of Oral and Maxillofacial Surgeons · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThis study evaluated the clinical efficacy of prolotherapy using hypertonic dextrose and polydeoxyribonucleotide (PDRN) in patients with temporomandibular joint disorders (TMDs) who did not respond to conventional treatments.
methodsA retrospective chart review of 66 patients diagnosed with TMD was conducted. Patients underwent prolotherapy between March and December 2024 and were classified into soft-tissue-related and bone-related TMD groups. Treatment involved injections of hypertonic dextrose or PDRN targeting anatomical structures within the temporomandibular joint (TMJ). Pain and function were assessed using the visual analog scale (VAS) and maximum mouth opening (MMO). Additional parameters, including joint sounds and jaw displacement (S deviation or L deflection), were analyzed. Outcomes were measured at baseline, after each prolotherapy session, and during the final follow-up. Statistical analyses included paired
resultsProlotherapy was administered an average of 2.3 times per patient. The baseline VAS score decreased from 4.34 ± 2.12 to 1.00 ± 1.58 (
conclusionsProlotherapy is an effective intervention for improving pain and jaw function in TMD patients. Both hypertonic dextrose and PDRN demonstrated significant clinical improvements on TMD prolotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.